戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              FGIDs are the dominant disease of acupuncture treatment,
2 n 699 subjects from a regional cohort of 466 FGID patients and 233 healthy controls.
3                      The era of diagnosing a FGID only when organic disease has been excluded is wani
4 dults with irritable bowel syndrome (IBS), a FGID that affects 5% to 10% of the population worldwide,
5 testing to support a positive diagnosis of a FGID.
6   We conducted a retrospective review of all FGID patients who underwent high resolution anorectal ma
7 n aged 8-17 years who were diagnosed with an FGID and a primary caretaker independently completed que
8 ent of chronic gastrointestinal symptoms and FGIDs.
9 d functional gastrointestinal disorders" (AP-FGID) has been changed to functional abdominal pain diso
10 hildren and adolescents with pain-associated FGIDs as defined by Rome IV and is not unique to either
11            This transition between different FGIDs suggests a common etiopathogenesis.
12 recommendations were generated for different FGIDs.
13 w insights have been gained in the different FGIDs in these age groups.
14  overview of the FGIDs field, differentiates FGIDs from motility and structural disorders, discusses
15       Functional gastrointestinal disorders (FGID) are common in the community.
16       Functional gastrointestinal disorders (FGID) are defined by a combination of chronic or recurre
17 g the functional gastrointestinal disorders (FGID) from a biopsychosocial perspective.
18       Functional gastrointestinal disorders (FGID) including impaired rectal evacuation are common in
19  with functional gastrointestinal disorders (FGID) often experience emotional distress, a perceived l
20 ms of functional gastrointestinal disorders (FGID), the "7*7" questionnaire developed by a working gr
21 lower functional gastrointestinal disorders (FGID).
22 tions in health and functional GI disorders (FGID).
23       Functional gastrointestinal disorders (FGIDs) are closely related to disorders of brain-gut int
24       Functional gastrointestinal disorders (FGIDs) are common conditions diagnosed by established sy
25 scent functional gastrointestinal disorders (FGIDs) has evolved during the two decade long Rome proce
26       Functional gastrointestinal disorders (FGIDs) have prominent sex differences in incidence, symp
27  with functional gastrointestinal disorders (FGIDs) often experience distress, reduced quality of lif
28 e and functional gastrointestinal disorders (FGIDs), and independently animal studies have explored m
29       Functional gastrointestinal disorders (FGIDs), now known as disorders of gut-brain interaction
30 nt of functional gastrointestinal disorders (FGIDs), now recognized as disorders of gut-brain interac
31       Functional gastrointestinal disorders (FGIDs), the most common diagnoses in gastroenterology ar
32  with functional gastrointestinal disorders (FGIDs), though mechanisms remain poorly defined and trea
33 ommon functional gastrointestinal disorders (FGIDs), which has now been renamed disorders of gut-brai
34 on of functional gastrointestinal disorders (FGIDs).
35 atric functional gastrointestinal disorders (FGIDs).
36 f the functional gastrointestinal disorders (FGIDs).
37  pathophysiology of functional GI disorders (FGIDs).
38 ional gastrointestinal intestinal disorders (FGIDs) in infants and toddlers was described.
39 going development of diagnostic criteria for FGID is therefore warranted.
40           Because of the paucity of data for FGIDs, we included data for non-gastrointestinal painful
41 s the primary pathophysiologic mechanism for FGIDs; this opens avenues for newer treatment modalities
42 robiome-targeted personalized treatments for FGIDs.
43 ors are significantly related to the Rome II FGID categories of functional oesophageal, bowel and ano
44 ion of various important factors that impact FGID but are often overlooked.
45 nsideration of important factors that impact FGIDs, such as gender, age, society, and the patient's p
46 e for sex- and gender-related differences in FGID, particularly irritable bowel syndrome (IBS).
47  evidence-based review on neuromodulators in FGID, restricted by the limited available controlled tri
48                The role of the NPS system in FGID deserves further study.
49 iants are associated with colonic transit in FGID.
50 iome, diet, and mucosal immune activation in FGIDs.
51 ional connections and functional activity in FGIDs patients, mainly including insula, anterior cingul
52 ess specific pathophysiological processes in FGIDs.
53 estinal symptoms and psychological status in FGIDs patients, and regulate functional connectivity and
54 probabilities were calculated for individual FGIDs.
55                                      Rome IV FGID definitions should enhance clarity for both clinici
56 IBS), functional abdominal pain (FAP), lower FGID-FD overlap, and high somatic symptom scores.
57  symptom subgroups including IBS, FAP, lower FGID-FD overlap, or high somatic symptom scores.
58 th different IBS or FAP phenotypes, or lower FGID-FD overlap.
59 (50.7% CC, 40.8% TC) and patients with lower FGID (8.6% TT, 51.5% CC, 40.8% TC, and 7.7% TT).
60 rom blood samples of 233 patients with lower FGID and 152 healthy controls.
61 beta3-C825T genotypes in patients with lower FGID and healthy controls and to test the associations o
62           There were 159 patients with lower FGID and overlap FD using Rome II criteria.
63 ciations of the GNbeta3 genotypes with lower FGID as a group, and subgroups of FGID and somatic sympt
64 ons of GNbeta3-C825T polymorphism with lower FGID overall or with the separate symptom subgroups incl
65 m is not associated significantly with lower FGID, with different IBS or FAP phenotypes, or lower FGI
66 rs on the meaning, expression, and course of FGID are important.
67 n of subjective distress in the diagnosis of FGID has consequences for actual prevalence rates of FGI
68 ct to ultimately result in the generation of FGID symptoms.
69   We sought to report the natural history of FGID in a US population.
70                       The natural history of FGID is unknown because of a lack of prospective populat
71                      Whereas the majority of FGID, including IBS, bloating, constipation, chronic fun
72  significant associations with phenotypes of FGID symptoms.
73                          Prevalence rates of FGID are high.
74                          Prevalence rates of FGID in our sample were similar to those in other studie
75  consequences for actual prevalence rates of FGID.
76  38.51% was found in the prevalence rates of FGID.
77 with lower FGID as a group, and subgroups of FGID and somatic symptom scores.
78  knowledge about the psychosocial aspects of FGIDs is fundamental and critical to the understanding,
79 cial pathophysiological conceptualization of FGIDs, and offers an approach to patient care.
80 ssemination of new knowledge in the field of FGIDs.
81                     Although the majority of FGIDs, including globus, rumination syndrome, IBS, bloat
82 fairly well established in the management of FGIDs and benefit from the newer serotonin norepinephrin
83 gnificantly improve the clinical symptoms of FGIDs patients, including abdominal pain, abdominal dist
84  research of acupuncture in the treatment of FGIDs patients.
85  gender and cross cultural understandings of FGIDs, 3) reduces the use of imprecise and occassionally
86 ntral mechanism and effect of acupuncture on FGIDs.
87 ng chronic gastrointestinal pain and painful FGIDs and serotonin noradrenergic reuptake inhibitors ca
88       Sleep problems are common in pediatric FGIDs and are associated with functional disability thro
89 and, ultimately, daily function in pediatric FGIDs.
90 on, but similar in patients who developed PI-FGID and recovered asymptomatic controls.
91 l symptoms after acute Giardia infection (PI-FGID), 19 recovered controls (RCs), and 16 healthy volun
92  an upward trend after 1 year in both the PI-FGID and RC groups.
93  14 months before normalizing in both the PI-FGID and RC groups.
94  in patients who did, or did not, develop PI-FGIDs.
95 us functional gastrointestinal disorders (PI-FGIDs).
96 rder patients very likely represent the same FGIDs that occur in non-ED patients.
97           No difference was seen by specific FGID or by sex, although adolescents were more likely to
98 and anorectal disorders, and to the specific FGIDs of IBS, functional abdominal bloating, functional
99                     In this web-based study, FGID were diagnosed using the Rome II criteria.
100                       We also point out that FGIDs can coexist with other medical conditions that the
101 idated bowel questionnaire characterized the FGID phenotype: 82 with IBS constipation, 94 with IBS di
102               Although the prevalence of the FGID was stable over time, the turnover in symptom statu
103 te to the development and maintenance of the FGID.
104                                          The FGIDs are a result of complex interactions between biolo
105 ent environmental stress, and several of the FGIDs but noted that this association is not specific to
106 low and offers an historical overview of the FGIDs field, differentiates FGIDs from motility and stru
107 ucing symptoms and other consequences of the FGIDs in children and adults.
108 ted that this association is not specific to FGIDs.
109 h have been shown to be efficacious to treat FGID.
110 f exciting new targets to identify and treat FGIDs and new areas for future research into their patho
111 dence-based review on their use for treating FGID syndromes.
112  low fiber, high simple sugar diet triggered FGID-related symptoms and decreased small intestinal mic
113 ored microbiome-driven mechanisms underlying FGIDs.
114 arge sample of children and adolescents with FGIDs; and, 2) to explore the impact of sleep by examini
115  the microbiota composition of patients with FGIDs are generally subtle, whereas changes in microbial

 
Page Top